The stock of Dynavax Technologies Corporation (NASDAQ:DVAX) is a huge mover today! About 361,513 shares traded hands. Dynavax Technologies Corporation (NASDAQ:DVAX) has declined 37.11% since March 15, 2016 and is downtrending. It has underperformed by 42.60% the S&P500.
The move comes after 9 months positive chart setup for the $398.47 million company. It was reported on Oct, 18 by Barchart.com. We have $13.85 PT which if reached, will make NASDAQ:DVAX worth $123.53M more.
Analysts await Dynavax Technologies Corporation (NASDAQ:DVAX) to report earnings on November, 3. They expect $-0.74 EPS, up 9.76% or $0.08 from last year’s $-0.82 per share. After $-0.75 actual EPS reported by Dynavax Technologies Corporation for the previous quarter, Wall Street now forecasts -1.33% EPS growth.
Dynavax Technologies Corporation (NASDAQ:DVAX) Ratings Coverage
Out of 2 analysts covering Dynavax Technologies (NASDAQ:DVAX), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. Dynavax Technologies has been the topic of 4 analyst reports since August 12, 2015 according to StockzIntelligence Inc. The firm earned “Sector Perform” rating on Thursday, April 28 by RBC Capital Markets. The rating was initiated by RBC Capital Markets on Monday, November 30 with “Outperform”. JP Morgan downgraded the shares of DVAX in a report on Wednesday, April 27 to “Neutral” rating. The stock has “Hold” rating given by Zacks on Wednesday, August 12.
According to Zacks Investment Research, “Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax’s clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.”
Insitutional Activity: The institutional sentiment decreased to 1.02 in Q2 2016. Its down 0.04, from 1.06 in 2016Q1. The ratio dived, as 18 funds sold all Dynavax Technologies Corporation shares owned while 34 reduced positions. 10 funds bought stakes while 43 increased positions. They now own 31.67 million shares or 4.27% less from 33.08 million shares in 2016Q1.
Moreover, Broadfin Capital Lc has 0.78% invested in Dynavax Technologies Corporation (NASDAQ:DVAX) for 547,810 shares. Teacher Retirement Sys Of Texas last reported 0% of its portfolio in the stock. Boston Advisors Llc has 0% invested in the company for 12,330 shares. The Pennsylvania-based Pnc Financial Grp Incorporated Incorporated has invested 0% in Dynavax Technologies Corporation (NASDAQ:DVAX). Falcon Point Cap accumulated 21,753 shares or 0.05% of the stock. Panagora Asset Management reported 340,600 shares or 0.02% of all its holdings. Howard Hughes Med Institute reported 21,355 shares or 0.1% of all its holdings. Moreover, Great West Life Assurance Can has 0% invested in Dynavax Technologies Corporation (NASDAQ:DVAX) for 3,673 shares. California Employees Retirement System reported 14,300 shares or 0% of all its holdings. Blackrock Fund Advsrs, a California-based fund reported 1.01M shares. Nelson Van Denburg Campbell Wealth Grp Lc holds 0% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX) for 100 shares. The New York-based Morgan Stanley has invested 0% in Dynavax Technologies Corporation (NASDAQ:DVAX). State Board Of Administration Of Florida Retirement System holds 0% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX) for 15,836 shares. D E Shaw Communications has 34,478 shares for 0% of their US portfolio. Citadel holds 0% or 28,713 shares in its portfolio.
Insider Transactions: Since May 12, 2016, the stock had 2 insider purchases, and 0 sales for $57,940 net activity. Another trade for 2,750 shares valued at $42,820 was bought by Gray Eddie. $15,120 worth of Dynavax Technologies Corporation (NASDAQ:DVAX) was bought by Janssen Robert on Thursday, May 12.
More recent Dynavax Technologies Corporation (NASDAQ:DVAX) news were published by: Investorplace.com which released: “Dynavax Technologies Corporation (DVAX) Steals Back Gains on Pending Heplisav …” on October 03, 2016. Also Investorplace.com published the news titled: “Dynavax Technologies Corporation (DVAX) Injected With 20%-Plus Gains” on September 06, 2016. Seekingalpha.com‘s news article titled: “Will Dynavax’ Hepsilav-B Ever Get Approved?” with publication date: October 14, 2016 was also an interesting one.
DVAX Company Profile
Dynavax Technologies Corporation (Dynavax), incorporated on November 6, 2000, is a clinical-stage biopharmaceutical company. The Firm uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. The Company’s development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg). The Company’s lead cancer immunotherapy candidate is SD-101, a C Class CpG TLR9 agonist is selected for characteristics optimal for treatment of cancer, including high interferon induction. The Company’s SD-101 clinical program is intended to assess the preliminary efficacy of SD-101 in a range of tumors and in combination with a range of treatments. The Company’s advanced inflammatory disease candidate is AZD1419. The Company’s pipeline of product candidates for cancer immunotherapy includes DV281 and CpG-Nanoparticles, which are in the preclinical stage.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.